Analysts move to downgrade Albireo Pharma after Ipsen's proposed acquisition

seekingalpha2023-01-12

Several analysts have downgraded their rating on biopharmaceutical company Albireo Pharma (NASDAQ:ALBO) in reaction to its deal to be acquired by France's Ipsen. Ipsen on Monday said it would buy ALBO...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2302883277?lang=en_US&edition=fundamental","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1359851661/image_1359851661.jpg","is_english":true,"pubTime":"2023-01-12 02:43","share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","id":"2302883277","market":"us","top_or_hot":-1,"title":"Analysts move to downgrade Albireo Pharma after Ipsen's proposed acquisition","media":"seekingalpha","content":"<div>\n<p>Several analysts have downgraded their rating on biopharmaceutical company Albireo Pharma (NASDAQ:ALBO) in reaction to its deal to be acquired by France's Ipsen. Ipsen on Monday said it would buy ALBO...</p>\n\n<a href=\"https://seekingalpha.com/news/3923856-analysts-move-to-downgrade-albireo-pharma-after-ipsens-proposed-acquisition\">Source Link</a>\n\n</div>\n","source":"seekingalpha","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Analysts move to downgrade Albireo Pharma after Ipsen's proposed acquisition</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAnalysts move to downgrade Albireo Pharma after Ipsen's proposed acquisition\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-01-12 02:43 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3923856-analysts-move-to-downgrade-albireo-pharma-after-ipsens-proposed-acquisition><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Several analysts have downgraded their rating on biopharmaceutical company Albireo Pharma (NASDAQ:ALBO) in reaction to its deal to be acquired by France's Ipsen. Ipsen on Monday said it would buy ALBO...</p>\n\n<a href=\"https://seekingalpha.com/news/3923856-analysts-move-to-downgrade-albireo-pharma-after-ipsens-proposed-acquisition\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ALBO","symbol_name":"Albireo Pharma, Inc.","start_time":0,"source_url":"https://seekingalpha.com/news/3923856-analysts-move-to-downgrade-albireo-pharma-after-ipsens-proposed-acquisition","article_id":"2302883277","we_media_id":null,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1359851661/image_1359851661.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2302883277","pubTimestamp":1673462610,"sourceInfo":{"source_id":"seekingalpha","name":"Seeking Alpha"},"weMediaInfo":null,"summary":"Several analysts have downgraded their rating on biopharmaceutical company Albireo Pharma (NASDAQ:AL","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"ALBO":"Albireo Pharma, Inc.","BK4139":"生物科技"},"translate_title":"益普生拟议收购后，分析师下调Albireo Pharma的评级","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ALBO":1},"content_text":"Several analysts have downgraded their rating on biopharmaceutical company Albireo Pharma (NASDAQ:ALBO) in reaction to its deal to be acquired by France's Ipsen. Ipsen on Monday said it would buy ALBO through a tender offer of $42/share for an estimated consideration of ~$952M plus a contingent value right of $10/share related to the U.S. approval of ALBO's lead drug candidate Bylvay.  ALBO shares surged to nearly double their value after the announcement of the acquisition. There were last up 0.7% at $44.14 in afternoon trading on Wednesday.  Boston, Ma.-based ALBO is developing Bylvay for several indications including progressive liver disease, bile buildup in the liver and the blockage of bile ducts. \"Given quite modest Bylvay sales thus far (FY22 guidance of $24M), yet-to-materialize commercial potential of additional indication and competition, we view potential counterbids as unlikely,\" Jefferies analyst Eun Yang said in a research note on Tuesday, while downgrading ALBO to hold from buy and cutting the price target to the acquisition price of $42. H.C. Wainwright analyst Ed Arce on Tuesday also downgraded ALBO to neutral with a $42 price target, stating that the key risks to the rating and price target include failure to complete the tender offer for ALBO shares. Additionally, Cowen analyst Ritu Baral downgraded ALBO to market perform from outperform, while Guggenheim's Seamus Fernandez downgraded ALBO to neutral from buy. Wall Street analysts and SA Authors rate ALBO a buy, while Seeking Alpha's Quant rating system gives it a strong buy.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2302883277"}